Farmas USA

" La política es la segunda profesión mas antigua del mundo , aunque a menudo se parezca a la primera..." R . Reagan

Bueno, tal y como dije, si el MACD no se mantenía THLD no pasaba de 7. Ha sido tocar los 7.00 exactos y empezar a recular, casi con prudencia. Aún así ha sido un muy buen cierre. Un 5.69% no se tiene todos los días.

Joer, hoy por subir ha subido hasta la infame "caralibro". Ojo a Bank of America (BAC) que espabila para atacar los 10 en breve.

jleon, muy bueno tu análisis técnico de AMRN. Creo que es la siguiente apuesta.

Señores cortoplacistas, ojito con ARNA. En cambio creo que ZLCS vaa seguir dando alegrías.

Saludos.

THLD 6,98 en after... aver si pronto nos da una buena alegría!!

Creo que ya esta puesto pero para animar......

Tuesday Trade: Why Zalicus News Merits My Very Bullish Call
June 19, 2012  | 8 comments  |  about: ZLCS, includes: COV, MRK, NVS, SNY

http://seekingalpha.com/article/670331-tuesday-trade-why-zalicus-news-merits-my-very-bullish-call

Si, pero al final cerro en negativo!!!, a ver si corrige, yo las solté a 1,26 y quiero volver a entrar!!!!! ;)

Pero en Afters està a 1,43

ZALICUS OPTIMISMO A TOPEEEEEEE!!
RESUMEN:
todos la ponen en 2-3$ este año. Y en 7-10$ quizas en un par de años.
La correccion de hoy, bajistas que venden con la noticia. Nada mas.
Gracias a Merck, Zalicus se nos pondra en 500 mill de capitalizacion/113 mill acciones = 4,4 $ accion ( su PO medio=4,17 )
Van viento en popa con sus dos lineas de investigacion y el 30 Septiembre es muy probable que la FDA de buenas noticias.

--------------------------------

"Nice news release before close. Buyers will come back in droves in the AM. Already up 3%+ after hours. Expecting a 10%+ move tomorrow on nothing new. If new news comes out, might run and pass today's high of $1.60+.

Silly low prices for this company. Lots of Volatily which means traders are going to be riding the waves up and down. We'll see higher high's and higher lows moving forward...Hold on to those shares. Even if just for a few more weeks. You'll see prices above $1.75+...easy money from here...

Tuesday's bear raid was more than "sell on the news" -- it was a feeble attempt to shake shares out of weak hands as Zalicus is on its way to go over $2/share, and from there $3/share. Why?

Simple. Because Merck (MRK) already offered Zalicus (in the past) up to $450 million for one ion channel drug. Zalicus, at this point, now has two. Even by low estimates, Zalicus is worth $500 million for its two ion channel drugs. With just over 100 million common shares in the market, this roughly explains how Dr. Duncan at JMP Securities has set a target of $5/share.

Just remember: Zalicus, despite this momentous achievement for its ion channel program, still has Exalgo with Covidien (COV), Prednisporin with Sanofi (SNY), and Synavive. All three of these drugs will drive a premium price. Toss on top of that pile the oncology work with Novartis (NVS), and you will see will today's orchestrated bear raid is a mere shadow of what is to come.

Like Jason Napodano at Zacks, I think Zalicus is worth every penny of $3/share and more likely $5/share set by Duncan at JMP Securities.

-----------------

Enjoy the ride up. Where else will you find a company this undervalued compared to it's peers and having a pipeline of drugs to support a 3-10 bagger from these levels in the future ahead...Might have to wait a year or two to see above $7-10 a share, but near short term in that $2-$3 range is highly likely."